PILOTING PRE-EMPTIVE PHARMACOGENETIC PANEL TESTING IN PRIMARY CARE: RECORDING OF PHARMACOGENETICS RESULTS AND REAL WORLD IMPACT.

被引：0
|
作者：
van der Wouden, C. H. [1 ]
Bank, P. C. D. [1 ]
Swen, J. J. [1 ]
Guchelaar, H. -J. [1 ]
机构：
[1] Leiden Univ, Med Ctr, Leiden, Netherlands
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2019年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PGRN-023
引用
收藏
页码：S21 / S21
页数：1
相关论文
共 13 条
  • [1] PILOTING PRE-EMPTIVE PHARMACOGENETIC PANEL TESTING IN PRIMARY CARE: RECORDING OF PHARMACOGENETICS RESULTS AND REAL WORLD IMPACT.
    van der Wouden, C. H.
    Bank, P. C. D.
    Swen, J. J.
    Guchelaar, H. -J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S114 - S114
  • [2] Pharmacist-Initiated Pre-Emptive Pharmacogenetic Panel Testing with Clinical Decision Support in Primary Care: Record of PGx Results and Real-World Impact
    van der Wouden, Cathelijne H.
    Bank, Paul C. D.
    Ozokcu, Kubra
    Swen, Jesse J.
    Guchelaar, Henk-Jan
    GENES, 2019, 10 (06):
  • [3] Estimating the potential impact of implementing pre-emptive pharmacogenetic testing in primary care across the UK
    Youssef, Essra
    Kirkdale, Charlotte L.
    Wright, David J.
    Guchelaar, Henk-Jan
    Thornley, Tracey
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (07) : 2907 - 2925
  • [4] Estimation of Impact of Implementing Pre-emptive Pharmacogenetic Testing in Hospital Treated Patients in Finland
    Kulla, N.
    Cajanus, K.
    Kyto, V
    Niemi, M.
    Tornio, A.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (SUPPL 1) : S101 - S101
  • [5] Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing
    van der Wouden, Cathelijne H.
    van Rhenen, Mandy H.
    Jama, Wafa O. M.
    Ingelman-Sundberg, Magnus
    Lauschke, Volker M.
    Konta, Lidija
    Schwab, Matthias
    Swen, Jesse J.
    Guchelaar, Henk-Jan
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 106 (04) : 866 - 873
  • [6] Estimation of impact of implementing pre-emptive pharmacogenetic testing in hospital-treated patients in Finland
    Kulla, Noora
    Litonius, Kaisa
    Cajanus, Kristiina
    Kyto, Ville
    Niemi, Mikko
    Tornio, Aleksi
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2023, 132 : 13 - 14
  • [7] A pilot study of the implementation of pharmacogenomic pharmacist initiated pre-emptive testing in primary care
    Paul C. D. Bank
    Jesse J. Swen
    Rowena D. Schaap
    Daniëlle B. Klootwijk
    Renée Baak – Pablo
    Henk-Jan Guchelaar
    European Journal of Human Genetics, 2019, 27 : 1532 - 1541
  • [8] A pilot study of the implementation of pharmacogenomic pharmacist initiated pre-emptive testing in primary care
    Bank, Paul C. D.
    Swen, Jesse J.
    Schaap, Rowena D.
    Klootwijk, Danielle B.
    Baak-Pablo, Renee
    Guchelaar, Henk-Jan
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 (10) : 1532 - 1541
  • [9] Longitudinal exposure of English primary care patients to pharmacogenomic drugs: An analysis to inform design of pre-emptive pharmacogenomic testing
    Kimpton, James E.
    Carey, Iain M.
    Threapleton, Christopher J. D.
    Robinson, Alexandra
    Harris, Tess
    Cook, Derek G.
    DeWilde, Stephen
    Baker, Emma H.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (12) : 2734 - 2746
  • [10] An economic model of the cost-utility of pre-emptive genetic testing to support pharmacotherapy in patients with major depression in primary care
    Reinier L. Sluiter
    Joost G. E. Janzing
    Gert Jan van der Wilt
    Wietske Kievit
    Martina Teichert
    The Pharmacogenomics Journal, 2019, 19 : 480 - 489
12